With tirzepatide and Mounjaro, the trigger is typically a combination of: Rapid weight loss (especially when it exceeds one to two pounds per week) Reduced overall caloric intake Insufficient protein consumption Deficiencies in key micronutrients, including iron, zinc, biotin, and vitamin D The hair shedding typically begins two to four months after the triggering event which means patients may not notice it until they have been on the medication for several months, sometimes leading them to attribute it to the drug directly
Cholestatic (bile-flow) pattern: ALT levels rise more than ALP levels, suggesting inflamed liver cells from a range of possible causes [5]
Limiting alcohol intake enhances treatment effectiveness and minimizes additional calories that could counteract weight management efforts
Five studies 14,21,33,35,36 , were identified which evaluated the effect of GLP-1-based therapies on IMT using longitudinal designs
If the rate of loss has slowed, this is often normal progression rather than medication failure